These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24034663)

  • 1. Nebivolol monotherapy in younger adults (younger than 55 years) with hypertension: a randomized, placebo-controlled trial.
    Giles TD; Khan BV; Lato J; Brener L; Ma Y; Lukic T
    J Clin Hypertens (Greenwich); 2013 Sep; 15(9):687-93. PubMed ID: 24034663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nebivolol monotherapy for patients with systolic stage II hypertension: results of a randomized, placebo-controlled trial.
    Lewin A; Punzi H; Luo X; Stapff M
    Clin Ther; 2013 Feb; 35(2):142-52. PubMed ID: 23332366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
    Germino FW
    Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of nebivolol in stage I-II hypertension: a pooled analysis of data from three randomized, placebo-controlled monotherapy trials.
    Weiss RJ; Saunders E; Greathouse M
    Clin Ther; 2011 Sep; 33(9):1150-61. PubMed ID: 21864908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial.
    Weiss RJ; Stapff M; Lin Y
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):129-40. PubMed ID: 23519546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of nebivolol: does age matter? A retrospective analysis of three randomized, placebo-controlled trials in stage I-II hypertension.
    Germino FW; Lin Y; Pejović V; Bowen L
    Ther Adv Cardiovasc Dis; 2012 Oct; 6(5):185-99. PubMed ID: 23008339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study.
    Giles TD; Weber MA; Basile J; Gradman AH; Bharucha DB; Chen W; Pattathil M;
    Lancet; 2014 May; 383(9932):1889-98. PubMed ID: 24881993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double-blind study.
    Rosei EA; Rizzoni D; Comini S; Boari G;
    Blood Press Suppl; 2003 May; 1():30-5. PubMed ID: 12800985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS).
    Czuriga I; Riecansky I; Bodnar J; Fulop T; Kruzsicz V; Kristof E; Edes I; ;
    Cardiovasc Drugs Ther; 2003 May; 17(3):257-63. PubMed ID: 14574084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic and antihypertensive effects of nebivolol and atenolol in normometabolic patients with mild-to-moderate hypertension.
    Pesant Y; Marc-Aurèle J; Bielmann P; Alaupovic P; Cartier P; Bichet D; Thibault G; Lupien PJ
    Am J Ther; 1999 May; 6(3):137-47. PubMed ID: 10423656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative assessment of antihypertensive efficacy of DL-nebivolol and D-nebivolol in patients with confirmed mild to moderate hypertension.
    Lacourcière Y; Poirier L; Lefebvre J; Archambault F; Cléroux J
    J Cardiovasc Pharmacol; 1995 Apr; 25(4):619-24. PubMed ID: 7596131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nebivolol efficacy and safety in patients with stage I-II hypertension.
    Greathouse M
    Clin Cardiol; 2010 Apr; 33(4):E20-7. PubMed ID: 20162736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nebivolol in hypertension: a double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life.
    Van Bortel LM; Breed JG; Joosten J; Kragten JA; Lustermans FA; Mooij JM
    J Cardiovasc Pharmacol; 1993 Jun; 21(6):856-62. PubMed ID: 7687708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nebivolol: in the treatment of hypertension in the US.
    Baldwin CM; Keam SJ
    Am J Cardiovasc Drugs; 2009; 9(4):253-60. PubMed ID: 19655820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and tolerability of nebivolol in hypertensive African American patients.
    Saunders E; Smith WB; DeSalvo KB; Sullivan WA
    J Clin Hypertens (Greenwich); 2007 Nov; 9(11):866-75. PubMed ID: 17978594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nebivolol withdrawal results in blood pressure returning toward pretreatment levels, but without rebound symptoms: phase IV randomized trial.
    Lewin A; Lasseter KC; Dong F; Whalen JC
    J Am Soc Hypertens; 2012; 6(3):228-36. PubMed ID: 22421631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nationwide efficacy-safety study of nebivolol in mildly hypertensive patients.
    Cleophas TJ; Agrawal R; Lichtenthal A; Mäkel W; Fici F
    Am J Ther; 2006; 13(3):192-7. PubMed ID: 16772759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients.
    Himmelmann A; Hedner T; Snoeck E; Lundgren B; Hedner J
    Eur J Clin Pharmacol; 1996; 51(3-4):259-64. PubMed ID: 9010695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Nebivolol, a third generation beta blocker: the modern treatment of hypertension. Results of a multicentric observational study].
    von Fallois J; Faülhaber HD
    Fortschr Med Orig; 2000 Jul; 118 Suppl 2():77-82. PubMed ID: 15700490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension.
    Weiss RJ; Weber MA; Carr AA; Sullivan WA
    J Clin Hypertens (Greenwich); 2007 Sep; 9(9):667-76. PubMed ID: 17786067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.